<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - SOMATROPIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>SOMATROPIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Gonadal dysgenesis (Turner syndrome)</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.4 mg/m2 daily, alternatively 45&#8211;50 micrograms/kg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Deficiency of growth hormone</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 150&#8211;300 micrograms daily, then increased if necessary up to 1 mg daily, dose to be increased gradually, use minimum effective dose (requirements may decrease with age).</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Dose formerly expressed in units; somatropin 1&#8239;mg &#8801; 3&#8239;units.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Discontinue if pregnancy occurs&#8212;no information available.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Evidence of tumour activity (complete antitumour therapy and ensure intracranial lesions inactive before starting)</li>
            <li>not to be used after renal transplantation</li>
            <li>not to be used for growth promotion in children with closed epiphyses (or near closure in Prader-Willi syndrome)</li>
            <li>severe obesity in Prader-Willi syndrome</li>
            <li>severe respiratory impairment in Prader-Willi syndrome</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Antibody formation, arthralgia, benign intracranial hypertension, carpal tunnel syndrome, fluid retention (peripheral oedema), headache, hyperglycaemia, hypoglycaemia, hypothyroidism, insulin resistance, leukaemia in children with growth hormone deficiency, myalgia, nausea, papilloedema, paraesthesia, reactions at injection site, visual problems, vomiting,
              </p>
        
        
            <section class="advice">
                <h3>Papilloedema</h3>
              <p>Funduscopy for papilloedema recommended if severe or recurrent headache, visual problems, nausea and vomiting occur&#8212;if papilloedema confirmed consider benign intracranial hypertension (rare cases reported).</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Rotate subcutaneous injection sites to prevent lipoatrophy.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA64</h3>
              <p outputclass="title">Somatropin for adults with growth hormone deficiency (August 2003)</p> <p>Somatropin is recommended in adults <b>only</b> if the following 3 criteria are fulfilled:</p> <ul> <li>Severe growth hormone deficiency, established by an appropriate method,</li> <li>Impaired quality of life, measured by means of a specific questionnaire,</li> <li>Already receiving treatment for another pituitary hormone deficiency.</li> </ul> <p>Somatropin treatment should be discontinued if the quality of life has not improved sufficiently by 9 months.</p> <p>Severe growth hormone deficiency developing after linear growth is complete but before the age of 25 years should be treated with growth hormone; treatment should continue until adult peak bone mass has been achieved. Treatment for adult-onset growth hormone deficiency should be stopped only when the patient and the patient&#8217;s physician consider it appropriate.</p> <p>Treatment with somatropin should be initiated and managed by a physician with expertise in growth hormone disorders; maintenance treatment can be prescribed in the community under a shared-care protocol.</p><xref format="html" href="http://www.nice.org.uk/TA64">www.nice.org.uk/TA64</xref>
                <a href="http://www.nice.org.uk/TA64" target="_blank">www.nice.org.uk/TA64</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA188</h3>
              <p outputclass="title">Somatropin for the treatment of growth failure in children (May 2010) </p> <p>Somatropin is recommended for children with growth failure who:</p> <ul> <li>have growth-hormone deficiency</li> <li>have Turner syndrome</li> <li>have Prader-Willi syndrome</li> <li>have chronic renal insufficiency</li> <li>are born small for gestational age with subsequent growth failure at 4 years of age or later</li> <li>have short stature homeobox-containing gene (SHOX) deficiency.</li> </ul> <p>Treatment should be discontinued if growth velocity increases by less than 50% from baseline in the first year of treatment.</p><xref format="html" href="http://www.nice.org.uk/TA188">www.nice.org.uk/TA188</xref>
                <a href="http://www.nice.org.uk/TA188" target="_blank">www.nice.org.uk/TA188</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Diabetes mellitus (adjustment of antidiabetic therapy may be necessary)
          </li>
          <li>
            disorders of the epiphysis of the hip (monitor for limping)
          </li>
          <li>
            history of malignant disease
          </li>
          <li>
            hypothyroidism&#8212;manufacturers recommend periodic thyroid function tests but limited evidence of clinical value
          </li>
          <li>
            initiation of treatment close to puberty not recommended in child born small for corrected gestational age
          </li>
          <li>
            papilloedema
          </li>
          <li>
            relative deficiencies of other pituitary hormones
          </li>
          <li>
            resolved intracranial hypertension (monitor closely)
          </li>
          <li>
            Silver-Russell syndrome
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Medicinal products containing somatropin are not identical and although there should be no important differences in terms of safety and efficacy, when prescribing biological products it is good practice to use the brand name.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of SOMATROPIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75165"><a href="../medicinalForm/PHP75165.html" data-target="#PHP75165" data-action="load">Solution for injection</a></div>
            <div id="PHP75158"><a href="../medicinalForm/PHP75158.html" data-target="#PHP75158" data-action="load">Powder and solvent for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
